Dihydroergotamine Shortage Update: What Patients Need to Know in 2026

If you or someone you love depends on Dihydroergotamine (DHE) to manage migraines or cluster headaches, you've probably felt the impact of the ongoing shortage. Pharmacies running out, long waits for refills, and scrambling for alternatives — it's been an exhausting experience for patients across the country.

Here's what you need to know about the Dihydroergotamine shortage as of 2026 — including the latest on availability, costs, and your options.

Is Dihydroergotamine Still in Shortage?

Yes, Dihydroergotamine Mesylate injection has been on the ASHP (American Society of Health-System Pharmacists) drug shortage list. While Hikma Pharmaceuticals, the primary generic manufacturer, has product available, supply remains inconsistent. Some pharmacies may have it in stock while others don't, and availability can change from week to week.

The nasal spray formulations (Migranal and Trudhesa) have also experienced intermittent availability issues, though for different reasons — limited manufacturers and high costs that reduce pharmacy stocking.

Why Is Dihydroergotamine Hard to Find?

The shortage comes down to a handful of factors that we've covered in detail in our article on why Dihydroergotamine is so hard to find. In short:

• Few manufacturers — Hikma is essentially the only producer of the generic injectable. When one company holds the supply, any disruption causes shortages.
• Complex production — Ergot alkaloids require specialized manufacturing, which limits how quickly production can scale.
• Growing demand — More headache specialists are turning to DHE for refractory migraines and infusion protocols.
• Brand discontinuation — The original D.H.E. 45 brand was discontinued, consolidating demand onto the generic.

What Does Dihydroergotamine Cost in 2026?

Costs vary widely depending on which formulation you're using and whether you have insurance:

• Generic injectable (Hikma) — Approximately $260-$500 with discount cards for a 10 mL supply.
• Migranal nasal spray — Around $400-$700 per package.
• Trudhesa nasal spray — Over $4,000 for 4 units without insurance, though manufacturer savings programs may bring it as low as $0 for eligible commercially insured patients.
• Brekiya autoinjector — Pricing still emerging as this product is newly approved (2025). Check with your pharmacy and insurance.

For a full breakdown of savings options, see our guide on how to save money on Dihydroergotamine.

New Options for Patients

There is some positive news. In 2025, the FDA approved two new Dihydroergotamine products that expand how patients can take this medication:

• Brekiya — The first DHE autoinjector. It delivers 1 mg of Dihydroergotamine via subcutaneous injection with a simple pen-like device. No need for clinic visits or IV infusions.
• Atzumi — A nasal powder formulation from Satsuma Pharmaceuticals. Unlike liquid nasal sprays, powder delivery may provide more consistent absorption and a faster onset of action.

These new formulations come from different manufacturers, which helps diversify the supply chain. However, as brand-name products, they are more expensive than the generic injectable and may require prior authorization.

How to Find Dihydroergotamine in Stock

If you need Dihydroergotamine right now, here's what to do:

1. Check Medfinder.com to see which pharmacies near you have it in stock.
2. Call independent pharmacies — they often have different supply sources than chains.
3. Ask your prescriber about different formulations (nasal spray, autoinjector) that may be available.
4. Contact your insurance about coverage for Trudhesa or Brekiya if the generic injectable is unavailable.
5. Read our detailed guide on finding Dihydroergotamine in stock for more tips.

Final Thoughts

The Dihydroergotamine shortage has been a long and frustrating challenge for migraine and cluster headache patients. While new FDA-approved formulations are expanding options, supply of the affordable generic injectable remains tight. Stay proactive by using Medfinder to track availability, working closely with your provider, and exploring all available formulations and savings programs. You deserve reliable access to the treatment that works for you.